Use Salix Pharmaceuticals Ltd. story together with your assets to enhance returns of your portfolios as well as to check it against diversification policy that fits your risk preferences.
by Anthony Paonita, editor in chief, Corporate Counsel Over after-work drinks at a midtown steakhouse I talked to Helen Wan, an associate general counsel at Time Inc. Wan, who is the primary in-house attorney for Time's lifestyle magazines (think ...
Story Momentum
This story from amlawdaily.typepad.com contributed to next trading day price increase. The story delta to the next closing price was 0.56% . The story delta to the current price is 8.55% .
IT Business Net - May 10, 2012
By GrabNetworks Salix Pharmaceuticals (SLXP) today had its estimates increased by Jefferies (JEF) after the company beat earnings estimates.
Junction Report - May 9, 2012
Salix Pharmaceuticals (NASDAQ: SLXP)'s stock had its ?neutral? rating restated by Zacks in a report issued on Wednesday. They currently have a $55.00 target price on the stock.
Auriga Reiterates Hold on Salix Pharmaceuticals (SLXP) - Movie News Guide (blog)
StreetInsider.com (subscription) - May 8, 2012
Jefferies analysts raised their price target on Salix Pharmaceuticals (NASDAQ: SLXP) from $54.00 to $63.00 while maintaining a BUY rating on the company.
Market Capitalization is total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.